<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953352</url>
  </required_header>
  <id_info>
    <org_study_id>19VADS01</org_study_id>
    <nct_id>NCT03953352</nct_id>
  </id_info>
  <brief_title>Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck Cancer Adaptive Radiotherapy</brief_title>
  <acronym>GIRAFE</acronym>
  <official_title>Evaluation of the Automatic Deformable Recontouring on the Daily MVCT for Head and Neck Cancer Adaptive Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a prospective, monocentric study aiming to evaluate an adaptive radiotherapy
      method (automatic deformable recontouring on the daily MVCT (MegaVoltage Computerized
      Tomography)) using the Precise ART™ software in patients with head and neck cancer.

      Patients will receive helical intensity-modulated radiotherapy (IMRT) according to the
      standard recommendations (35 fractions during 7 weeks). Radiotherapy will include daily
      repositioning MVCT.

      For the study, patients will undergo 4 intermediate re-planning CT-scan (without injection of
      intravenous contrast agent) at week 3, week 4, week 5 and week 6 of treatment.

      3 recontouring modalities will be evaluated for the study:

        -  Manuel recontouring (standard method)

        -  Precise ART™ deformed contours

        -  Precise RTX™ deformed contours

      The total duration of the study for each patient will be 7 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with Dice Similarity Coefficient (DSC) of the volumes of left and right parotid gland superior to 0.85 (DSC &gt; 0.85)</measure>
    <time_frame>7 weeks for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with DSC &gt; 0.85 for other organs at risk (oral cavity, medullar canal, mandible,brain stem, larynx)</measure>
    <time_frame>7 weeks for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with DSC &gt; 0.85 for target volumes (clinical target volume, gross target volume, planning target volume)</measure>
    <time_frame>7 weeks for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time saving defined by the difference between standard recontouring time (manuel recontouring) and experimental recontouring time (Precise ART™ or Precise RTX™)</measure>
    <time_frame>7 weeks for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Radiotherapy treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Helical intensity-modulated radiotherapy (IMRT)</intervention_name>
    <description>Helical intensity-modulated radiotherapy (35 fractions, 5 fractions per week) will be administered during 7 weeks: 2 Gy per fraction on tumor and 1.6 Gy per fraction on bilateral lymph node areas.</description>
    <arm_group_label>Radiotherapy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old

          2. Patient with histologically proven locally advanced head and neck cancer (Oropharynx,
             hypopharynx, larynx, nasopharynx, oral cavity, sinuses, nasal cavities, ethmoid sinus,
             cavum, salivary glands)

          3. Cancer with nodal involvement (at least T3 or involved node &gt;2 cm)

          4. Eastern Cooperative Oncology Group performance status 0 or 1

          5. No previous curative treatment for head and neck cancer (surgery and/or radiotherapy
             and/or chemotherapy)

          6. Indication of exclusive radiotherapy (+/- chemotherapy) validated in multidisciplinary
             meeting

          7. Patient affiliated to the french social security system.

          8. Patient must provide written informed consent prior to inclusion in the study and any
             study-specific procedure.

        Exclusion Criteria:

          1. Patient with metastatic cancer

          2. Eastern Cooperative Oncology Group performance status ≥ 2 (due to comorbidities)

          3. Patient with recurrent disease

          4. Patient who required urgent surgical treatment

          5. Contraindications to radiotherapy

          6. History of cancer within 5 years

          7. Patient already included in another therapeutic trial

          8. Pregnant or breastfeeding women

          9. Any psychological, familial, geographical or sociological condition potentially
             preventing the medical follow-up and/or study procedures

         10. Patient protected by law
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>LAPRIE Anne</last_name>
    <phone>05 31 15 54 43</phone>
    <email>laprie.anne@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Universitaire Du Cancer Toulouse - Oncopole (Iuct-O)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LAPRIE Anne</last_name>
      <phone>05 31 15 54 43</phone>
      <email>laprie.anne@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adaptive radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

